2023 World Conference on Lung Cancer (Posters)-EP11.01. ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-Small-Cell Lung Cancer Immunotherapy Trials

EP11.01. ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-Small-Cell Lung Cancer Immunotherapy Trials - PDF(Abstract)

Back to course

Pdf Summary

This document discusses a novel scoring system, called ICTIS, that assesses the inclusivity of immunotherapy trials for metastatic non-small cell lung cancer (NSCLC). The authors highlight that although immunotherapy has significantly improved outcomes for lung cancer patients, many clinical trials have restrictive criteria that exclude a large number of patients, leading to disparities in healthcare outcomes. The ICTIS scoring system, consisting of 22 points divided into subcategories, measures the inclusivity of trials based on publicly available eligibility criteria. The authors accessed recruiting and not-yet-recruiting immunotherapy trials from ClinicalTrials.gov and scored them using ICTIS. They found that a higher ICTIS score indicates higher inclusivity and increased access to immunotherapy. However, they also noted that despite national guidelines for improving inclusivity, immunotherapy trials have made little effort to broaden their eligibility criteria. They found that the majority of eligibility criteria were uniform across different treatments, phases of trial, and lines of treatment, despite the different purposes and risk profiles of the subgroups. No significant differences were found when comparing trials from different time periods and lines of treatment. The authors conclude that their scoring system provides a tool to assess clinical trial inclusivity and can help investigators design immunotherapy studies to improve patient access and generalize the results.

Asset Subtitle

Nagashree Seetharamu

Meta Tag

Speaker Nagashree Seetharamu

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

ICTIS

inclusivity

immunotherapy trials

eligibility criteria

access to immunotherapy

clinical trials

disparities in healthcare outcomes

broaden eligibility criteria

risk profiles

patient access